{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:42:34Z","timestamp":1792676554062,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007366","name":"Italian Multiple Sclerosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neurol.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:37:40Z","timestamp":1776857860000},"page":"467-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of Epstein-Barr virus in multiple sclerosis: From pathogenesis to therapeutic potential"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-1699","authenticated-orcid":false,"given":"G.","family":"Bellucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mechelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ristori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0501-8803","authenticated-orcid":false,"given":"M.","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.04.002_bib0170","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neurol.2026.04.002_bib0175","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2026.04.002_bib0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2026.04.002_bib0185","doi-asserted-by":"crossref","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.neurol.2026.04.002_bib0190","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","article-title":"Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis","volume":"186","author":"Vietzen","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2026.04.002_bib0195","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418783122","article-title":"A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis","volume":"122","author":"Mechelli","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2026.04.002_bib0200","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.neuron.2022.12.029","article-title":"Virus exposure and neurodegenerative disease risk across national biobanks","volume":"111","author":"Levine","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2026.04.002_bib0205","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41582-025-01144-0","article-title":"The multiple sclerosis prodrome: insights into how and when disease starts","volume":"21","author":"Tremlett","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.04.002_bib0210","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurol.2026.04.002_bib0215","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1093\/brain\/awr197","article-title":"Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria","volume":"134","author":"Lassmann","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.04.002_bib0220","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(22)00471-9","article-title":"Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy","volume":"22","author":"Aloisi","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.04.002_bib0225","doi-asserted-by":"crossref","first-page":"eadl3604","DOI":"10.1126\/sciimmunol.adl3604","article-title":"Altered immune landscape of cervical lymph nodes reveals Epstein-Barr virus signature in multiple sclerosis","volume":"10","author":"Sarkkinen","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.neurol.2026.04.002_bib0230","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425670122","article-title":"Epstein-Barr virus and the immune microenvironment in multiple sclerosis: insights from high-dimensional brain tissue imaging","volume":"122","author":"Orr","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2026.04.002_bib0235","doi-asserted-by":"crossref","first-page":"e1009618","DOI":"10.1371\/journal.ppat.1009618","article-title":"Epigenetic plasticity enables CNS-trafficking of EBV-infected B lymphocytes","volume":"17","author":"Soldan","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.neurol.2026.04.002_bib0240","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41586-025-09378-0","article-title":"EBV induces CNS homing of B cells attracting inflammatory T cells","volume":"646","author":"L\u00e4derach","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2026.04.002_bib0245","doi-asserted-by":"crossref","first-page":"102027","DOI":"10.1016\/j.xcrm.2025.102027","article-title":"T-bet+ CXCR3+ B cells drive hyperreactive B-T cell interactions in multiple sclerosis","volume":"6","author":"Jelcic","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.neurol.2026.04.002_bib0250","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2025.12.031","article-title":"T. Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation","volume":"189","author":"Kim","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2026.04.002_bib0255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41582-023-00838-7","article-title":"Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis","volume":"19","author":"Magliozzi","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.04.002_bib0260","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3390\/pathogens13060499","article-title":"Cytomegalovirus, Epstein-Barr virus, Herpes Simplex virus, and Varicella Zoster virus infection dynamics in people with multiple sclerosis from Northern Italy","volume":"13","author":"Maple","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.neurol.2026.04.002_bib0265","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/1352458511410515","article-title":"Epstein-Barr virus nuclear antigen-1 B-cell epitopes in multiple sclerosis twins","volume":"17","author":"Mechelli","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.04.002_bib0270","doi-asserted-by":"crossref","first-page":"e184481","DOI":"10.1172\/JCI184481","article-title":"Accumulation of Epstein-Barr virus-induced cross-reactive immune responses is associated with multiple sclerosis","volume":"134","author":"Vietzen","year":"2024","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.neurol.2026.04.002_bib0275","doi-asserted-by":"crossref","first-page":"ugag019","DOI":"10.1093\/narmme\/ugag019","article-title":"EBV genome analysis in multiple sclerosis shows extensive viral diversity and links to autoimmunity","volume":"3","author":"Lehikoinen","year":"2026","journal-title":"NAR Molecular Medicine"},{"key":"10.1016\/j.neurol.2026.04.002_bib0280","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2025.12.046","article-title":"EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation","volume":"189","author":"Wang","year":"2026","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.neurol.2026.04.002_bib0285","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2025.12.032","article-title":"Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis","volume":"189","author":"Thomas","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2026.04.002_bib0290","article-title":"Systematic investigation reveals extensive Epstein-Barr virus transcriptional regulation of the human genome","author":"Dexheimer","year":"2025","journal-title":"bioRxiv [Preprint]"},{"key":"10.1016\/j.neurol.2026.04.002_bib0295","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.chom.2016.01.006","article-title":"The evolution of antiviral defense systems","volume":"19","author":"tenOever","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.neurol.2026.04.002_bib0300","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/gene.2008.35","article-title":"Variations of the perforin gene in patients with multiple sclerosis","volume":"9","author":"Cappellano","year":"2008","journal-title":"Genes Immun"},{"key":"10.1016\/j.neurol.2026.04.002_bib0305","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1177\/1352458520963937","article-title":"PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity","volume":"27","author":"Sidore","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.04.002_bib0310","doi-asserted-by":"crossref","first-page":"105436","DOI":"10.1016\/j.msard.2024.105436","article-title":"Antiviral therapy with tenofovir in MS","volume":"83","author":"Torkildsen","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.04.002_bib0315","doi-asserted-by":"crossref","first-page":"12368","DOI":"10.1073\/pnas.2002392117","article-title":"Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase","volume":"117","author":"Drosu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2026.04.002_bib0320","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40263-024-01153-5","article-title":"Repurposing licensed drugs with activity against Epstein-Barr virus for treatment of multiple sclerosis: a systematic approach","volume":"39","author":"Li","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2026.04.002_bib0325","doi-asserted-by":"crossref","first-page":"105364","DOI":"10.1016\/j.msard.2023.105364","article-title":"Emboldened or not: the potential fall-out of a failed anti-EBV trial in multiple sclerosis","volume":"81","author":"Giovannoni","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.04.002_bib0330","doi-asserted-by":"crossref","first-page":"887794","DOI":"10.3389\/fneur.2022.887794","article-title":"The potential for EBV vaccines to prevent multiple sclerosis","volume":"13","author":"Maple","year":"2022","journal-title":"Front Neurol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:15:16Z","timestamp":1792674916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0035378726005084"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.04.002","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of Epstein-Barr virus in multiple sclerosis: From pathogenesis to therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}